文献速递乳房整形与再造

即时乳房再造的肿瘤学安全性:138例患者单中心回顾性分析

Oncologic Safety of Immediate Breast Reconstruction: A Single-Center Retrospective Review of 138 Patients.
PubMed 文献 · Ann Plast Surg · 2021-01-01

该单中心回顾性研究分析了2012年1月至2019年12月间138例接受乳房切除联合即时乳房再造(IBR)的浸润性和原位乳腺癌患者的肿瘤学安全性,平均随访49.3个月(范围8-104个月),局部复发5例、局部复发伴远处转移1例、全身复发2例,总生存率97.8%,无病生存率94.2%,结论认为IBR对复发和生存无负面影响,但需更长期随访确认。

要点

  • 138例乳房切除联合即时乳房再造患者中,重建失败率为8.7%。
  • 平均随访49.3个月(范围8-104个月)内,局部复发5例、局部复发伴远处转移1例、全身复发2例。
  • 总生存率97.8%,无病生存率94.2%,作者认为IBR对复发或生存无负面影响。

核心结论

  • 本综述中患者癌症复发发生率低。
  • 乳房切除后即时乳房再造对复发或患者生存无负面影响,即使晚期疾病患者亦然。
  • 研究结果表明,乳房切除联合IBR对于浸润性和非浸润性乳腺癌患者可是安全的手术选择。
  • 需要更长期随访以确认这些初步结果。

研究设计与样本

  • 单中心(比利时CHU UCL Namur)回顾性综述。
  • 分析接受乳房切除联合即时乳房再造的浸润性和原位乳腺癌患者的肿瘤学安全性。
  • 排除接受姑息性手术的患者和诊断为乳腺肉瘤的患者。
  • 回顾性分析2012年1月至2019年12月间接受乳房切除和IBR的138例患者。

主要发现

  • 大多数重建手术采用腹壁下深动脉穿支游离皮瓣(55.1%)。
  • 重建失败率为8.7%。
  • 平均随访49.3个月(范围8-104个月)期间,识别出局部癌症复发5例、局部癌症复发伴远处转移1例、全身复发2例。
  • 总生存率为97.8%,无病生存率为94.2%。

临床怎么用

  • 作者认为,乳房切除联合IBR对于浸润性和非浸润性乳腺癌患者可是安全的手术选择。

局限性

  • 需要更长期随访以确认这些初步结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The purpose of this study was to assess the oncologic safety of mastectomies associated with immediate breast reconstruction (IBR) in terms of recurrence and survival. METHODS: A retrospective review was conducted at a single center (CHU UCL Namur, Belgium). We analyzed the oncologic safety of IBR for patients with invasive and in situ breast cancer who underwent mastectomy associated with IBR. Patients who underwent palliative surgery and those with a diagnosis of breast sarcoma were excluded. RESULTS: We retrospectively analyzed 138 patients who underwent mastectomy and IBR between January 2012 and December 2019. Most reconstruction procedures used deep inferior epigastric perforator free flaps (55.1%). The reconstructive failure rate was 8.7%. Among the patients included, 5 cases of local cancer recurrence, 1 case of local cancer recurrence associated with distant metastasis, and 2 cases of systemic recurrence were identified during a mean follow-up of 49.3 months (range, 8-104 months) after surgery. Overall survival was 97.8%, and disease-free survival was 94.2%. CONCLUSIONS: Patients had a low incidence of cancer recurrence in this review. Immediate breast reconstruction after mastectomy had no negative impact on recurrence or patient survival, even in patients with advanced disease. The study findings suggest that mastectomy associated with IBR can be a safe surgical option for patients with invasive and noninvasive breast cancers. Longer follow-ups are needed to confirm these preliminary results.

来源:Ann Plast Surg,查看原文。版权归原作者所有。

引用

  1. Hammer J, Servaes M, Berners A, et al. Oncologic Safety of Immediate Breast Reconstruction: A Single-Center Retrospective Review of 138 Patients. Ann Plast Surg. 2021. PMID: 34818286. doi:10.1097/SAP.0000000000002869

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。